Bispecific T-Cell Engager Senolytics (uPAR-GFD-CD3)
Current understanding
Bispecific T-cell engagers (BiTEs) directed at senescent-cell surface antigens — notably a uPAR-targeting GFD-CD3 construct — are being proposed as a dose-titratable, ‘off-the-shelf’ alternative to senolytic CAR T cells. The lead preclinical package reports senescent-cell clearance and alleviation of age-related pathologies in aged mice and non-human primates, with serum aminotransferase activity used as a titration/safety biomarker [animal-model]. No human aging data; oncology-derived cytokine release and on-target/off-target toxicity concerns carry over, as do questions about durability of effect compared with cell-based approaches [expert-opinion].
Evidence log
- 2026-09-29 — uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor: 2026 preclinical study of uPAR-GFD-CD3 BiTE shows senescent-cell clearance in aged mice and non-human primates, with serum ALT/AST proposed as a titration/safety biomarker — first NHP data on the platform, still no human efficacy. [animal-model] (novelty: 4)
- 2026-10-01 — uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.: cross-connection with car-t-senolytics: Both target uPAR on senescent cells via redirected T-cell killing; BiTEs trade the persistence of engineered cells for pharmacologic dose titration and a serum-aminotransferase safety readout. (novelty: 4)